338 related articles for article (PubMed ID: 16312864)
1. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P
J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864
[No Abstract] [Full Text] [Related]
2. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia.
Maiolo AT; Foa P; Cortellaro M; Lambertenghi-Deliliers G; Colantoni A; Cesana B; Castoldi GL; Cazzola M; Giordano M; Riccardi A
Haematologica; 1987; 72(1):61-5. PubMed ID: 3108098
[No Abstract] [Full Text] [Related]
3. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
4. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
Katayama N; Tanaka I; Minami N; Shirakawa S
Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
[TBL] [Abstract][Full Text] [Related]
5. [Acute myeloblastic leukemias and myelodysplasias: treatment with low doses of aracytine].
Pignon B; Blaise AM; Boilletot A; Herbrecht R; Rozenbaum A; Flesch M; Audhuy B; Barats JC
Nouv Rev Fr Hematol (1978); 1986; 28(6):345-8. PubMed ID: 3470706
[TBL] [Abstract][Full Text] [Related]
6. Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
Insiripong S; Thaisamakr S
J Med Assoc Thai; 1996 Sep; 79(9):568-71. PubMed ID: 8996985
[TBL] [Abstract][Full Text] [Related]
7. Results of aggressive chemotherapy for myelodysplastic syndromes.
Dohy H; Kyo T
Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1428-34. PubMed ID: 3247817
[No Abstract] [Full Text] [Related]
8. [Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
Tsubaki K; Horiuchi A; Nagai K; Kanamaru A; Kohsaki M; Kitani T; Tagawa S; Masaoka T; Shibata H; Yasunaga K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):996-1003. PubMed ID: 3457553
[TBL] [Abstract][Full Text] [Related]
9. [Low doses of subcutaneous cytosine arabinoside in the treatment of patients with myelodysplastic syndromes].
Avilés A; Tripp F; Velásquez A; Rubio ME; González-Llavén J
Rev Invest Clin; 1988; 40(1):21-4. PubMed ID: 3165541
[No Abstract] [Full Text] [Related]
10. [Successful treatment of acute non-lymphoblastic leukemia from myelodysplastic syndrome by combination of human macrophage colony-stimulating factor (M-CSF) and low dose cytosine arabinoside: M-CSF-induced proliferation and tyrosine phosphorylation in leukemic blasts].
Hagiwara S; Yuo A; Nagai M; Takezako N; Soda Y; Miwa A; Togawa A; Takaku F
Rinsho Ketsueki; 1996 Nov; 37(11):1259-64. PubMed ID: 8960658
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of low-dose cytarabine therapy in myelodysplastic syndromes.
el-Mangoush M; Singh NK
J Assoc Physicians India; 1992 Jul; 40(7):452-4. PubMed ID: 1484026
[TBL] [Abstract][Full Text] [Related]
12. [Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine].
Waage A; Hammerstrøm J; Lødemel B; Hoff JE; Langtind J
Tidsskr Nor Laegeforen; 1986 Feb; 106(6):496-7. PubMed ID: 3457484
[No Abstract] [Full Text] [Related]
13. An inexpensive way to treat elderly patients with high-risk MDS or AML.
Kuendgen A
Leuk Res; 2011 Aug; 35(8):985-6. PubMed ID: 21561661
[No Abstract] [Full Text] [Related]
14. Anterior uveitis associated with high-dose cytosine arabinoside.
Fintelmann RE; Qian Y; Skalet A; Jeng BH
Ocul Immunol Inflamm; 2010 Dec; 18(6):485-7. PubMed ID: 20887203
[TBL] [Abstract][Full Text] [Related]
15. Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
Nair R; Saikia TK; Gopal R; Nair CN; Soman CS; Advani SH
J Assoc Physicians India; 1996 Mar; 44(3):181-3. PubMed ID: 9251314
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Natarajan-Amé S; Park S; Ades L; Vey N; Guerci-Bresler A; Cahn JY; Etienne G; Bordessoule D; Ravoet C; Legros L; Cheze S; Stamatoullas A; Berger E; Schmidt A; Charbonnier A; Chaury MP; Braun T; Fenaux P; Dreyfus F;
Br J Haematol; 2012 Jul; 158(2):232-237. PubMed ID: 22571447
[TBL] [Abstract][Full Text] [Related]
17. Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Corsetti MT; Salvi F; Perticone S; Baraldi A; De Paoli L; Gatto S; Pietrasanta D; Pini M; Primon V; Zallio F; Tonso A; Alvaro MG; Ciravegna G; Levis A
Leuk Res; 2011 Aug; 35(8):991-7. PubMed ID: 21474179
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 (1 alpha(OH)D3)].
Taoka T; Hamamoto T; Okuda Y; Hata Y; Kubota Y; Tanaka T; Irino S; Miyazaki T; Ohbayashi S
Rinsho Ketsueki; 1987 Jun; 28(6):830-8. PubMed ID: 3478504
[No Abstract] [Full Text] [Related]
19. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
20. Low dose Ara-C for patients with myelodysplastic syndromes.
Powell BL; Capizzi RL; Jackson DV; Richards F; Muss HB; Lyerly ES; Rosenbaum DL; Connelly RA; Buss DH; Bearden JD
Leukemia; 1988 Mar; 2(3):153-6. PubMed ID: 3347093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
